HK1202533A1 - 替格瑞洛的中間體及其製備方法和替格瑞洛的製備方法 - Google Patents

替格瑞洛的中間體及其製備方法和替格瑞洛的製備方法

Info

Publication number
HK1202533A1
HK1202533A1 HK15102985.6A HK15102985A HK1202533A1 HK 1202533 A1 HK1202533 A1 HK 1202533A1 HK 15102985 A HK15102985 A HK 15102985A HK 1202533 A1 HK1202533 A1 HK 1202533A1
Authority
HK
Hong Kong
Prior art keywords
ticagrelor
preparation
intermediates
methods
preparation methods
Prior art date
Application number
HK15102985.6A
Other languages
English (en)
Inventor
黃金昆
孫紹光
宋德福
何彪
賴小波
Original Assignee
Jiangsu Hengrui Medicine Co
Suncadia Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co, Suncadia Pharmaceuticals Co Ltd filed Critical Jiangsu Hengrui Medicine Co
Publication of HK1202533A1 publication Critical patent/HK1202533A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
HK15102985.6A 2013-04-10 2015-03-24 替格瑞洛的中間體及其製備方法和替格瑞洛的製備方法 HK1202533A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201310122613 2013-04-10

Publications (1)

Publication Number Publication Date
HK1202533A1 true HK1202533A1 (zh) 2015-10-02

Family

ID=51667139

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15102985.6A HK1202533A1 (zh) 2013-04-10 2015-03-24 替格瑞洛的中間體及其製備方法和替格瑞洛的製備方法

Country Status (7)

Country Link
US (1) US9359366B2 (zh)
EP (1) EP2985286B1 (zh)
JP (1) JP6332818B2 (zh)
CN (2) CN107573333B (zh)
HK (1) HK1202533A1 (zh)
TW (1) TWI634116B (zh)
WO (1) WO2014166324A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
CZ2013866A3 (cs) * 2013-11-08 2015-05-20 Zentiva, K.S. Způsob výroby a nová krystalická forma intermediátu syntézy ticagreloru
CN105801583A (zh) * 2014-12-31 2016-07-27 徐州万邦金桥制药有限公司 一种替格瑞洛的纯化方法
CN105859720A (zh) * 2015-01-20 2016-08-17 上海方楠生物科技有限公司 一种替格瑞洛溶液的制备方法
CN105669681A (zh) * 2016-04-11 2016-06-15 成都华宇制药有限公司 一种替格瑞洛的合成方法
CN111848632A (zh) * 2020-09-07 2020-10-30 河南师范大学 一种血小板聚集抑制剂替格瑞洛的制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0577558A2 (de) * 1992-07-01 1994-01-05 Ciba-Geigy Ag Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte
RU2153494C2 (ru) * 1993-10-12 2000-07-27 Дзе Дюпон Мерк Фармасьютикал Компани 1-n-алкил-n-арилпиримидинамины, способ лечения заболеваний, фармацевтическая композиция
AR017014A1 (es) * 1997-07-22 2001-08-22 Astrazeneca Ab Compuestos de triazolo [4,5-d]pirimidina, composiciones farmaceuticas, uso de los mismos para preparar medicamentos y procesos para la preparacionde dichos compuestos
TWI229674B (en) * 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
GB0013407D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound
GB0013488D0 (en) 2000-06-02 2000-07-26 Astrazeneca Ab Chemical compound
CN101148450A (zh) * 2007-11-02 2008-03-26 严红芳 一种核苷化合物的制备方法
ES2558843T3 (es) * 2008-09-09 2016-02-09 Astrazeneca Ab Procedimiento para preparar [1S-[1-alfa,2-alfa,3-beta(1S*,2R*),5-beta]]-3-[7-[2-(3,4-difluorofenil)-ciclopropilamino]-5-(propiltio)-3H-1,2,3-triazolo[4,5-d]pirimidin-3-il]-5-(2-hidroxietoxi)ciclopentano-1,2-diol y a sus productos intermedios
EP2459564B1 (en) 2009-07-27 2016-09-07 Auspex Pharmaceuticals, Inc. Cyclopropyl modulators of p2y12 receptor
MX2013007115A (es) 2010-12-20 2014-02-10 Actavis Group Ptc Ehf Procesos novedosos para preparar derivados de triazolo[4, 5 - d] pirimidina e intermediarios de los mismos.
CA2832570A1 (en) * 2011-04-06 2012-10-11 Teva Pharmaceutical Industries Ltd. New intermediates and processes for preparing ticagrelor
WO2013060837A1 (en) * 2011-10-27 2013-05-02 Lek Pharmaceuticals D.D. Synthesis of triazolopyrimidine compounds
EP2794575B1 (en) * 2011-12-23 2018-12-05 LEK Pharmaceuticals d.d. Synthesis of triazolopyrimidine compounds
WO2013150495A2 (en) * 2012-04-05 2013-10-10 Dr. Reddy's Laboratories Limited Preparation of ticagrelor
CN102659815B (zh) 2012-05-04 2013-07-17 开原亨泰制药股份有限公司 一种制备选择性抗凝血药替卡格雷及其中间体的方法
CN102675321B (zh) * 2012-05-11 2014-12-10 上海皓元化学科技有限公司 一种替卡格雷的制备方法
CN102875537A (zh) * 2012-09-10 2013-01-16 常州制药厂有限公司 一种新的抗血栓药物的制备方法

Also Published As

Publication number Publication date
CN104098553B (zh) 2017-11-28
US20160052928A1 (en) 2016-02-25
CN107573333A (zh) 2018-01-12
CN107573333B (zh) 2019-10-18
US9359366B2 (en) 2016-06-07
CN104098553A (zh) 2014-10-15
TWI634116B (zh) 2018-09-01
EP2985286A4 (en) 2016-09-14
EP2985286A1 (en) 2016-02-17
JP6332818B2 (ja) 2018-05-30
JP2016515635A (ja) 2016-05-30
EP2985286B1 (en) 2017-10-11
TW201439087A (zh) 2014-10-16
WO2014166324A1 (zh) 2014-10-16

Similar Documents

Publication Publication Date Title
IL290547A (en) Antibodies and methods of use
HK1216380A1 (zh) 附接裝置以及使用和製造的相關聯的方法
GB2535360B (en) Methods of preparing polyhemiaminals and polyhexahydrotriazines
IL244495A0 (en) Anti-alpha-synuclein antibodies and methods of use
HK1213476A1 (zh) 取代的三唑並吡啶及其使用方法
IL286759A (en) Therapeutic methods and preparations
HK1221416A1 (zh) 氧雜雙環庚烷和氧雜雙環庚烯的配製品
HK1225612A1 (zh) 抗ly6e抗體及使用方法
GB201301626D0 (en) Composition comprising 15-OHEPA and methods of using the same
EP3054974A4 (en) Glycan-interacting compounds and methods of use
HK1224307A1 (zh) 原毒素- 變體及其使用方法
HK1202533A1 (zh) 替格瑞洛的中間體及其製備方法和替格瑞洛的製備方法
IL242943A0 (en) A process for the preparation of abiraterone and its intermediates
SG11201507389RA (en) Integration of hydro-dechlorination and hydro-regeneration
HK1213882A1 (zh) 用於製備普瑞巴林的方法和中間體
IL241290A0 (en) Subprevir polymorphs and methods for their production
EP3027182A4 (en) Novel copper-cysteamine and methods of use
SG11201602693QA (en) Methods and intermediates for preparing macrolactams
PL3071575T3 (pl) Wytwarzanie normorfinanów
HUP1300722A2 (en) Norsteroid intermediates and process for their preparation
AU2013902711A0 (en) Compounds and methods of their use - IV
GB201319255D0 (en) Therapeutic compositions and methods